Catheter Precision Launches LockeT in Italy with Commercial Purchase Order.

Catheter Precision, a medical device company, has introduced LockeT in Italy after successful procedures and clinical acceptance in France and Germany. The first procedures in Italy were performed at ASST Valle Olona Hospital under Dr. Manuela Bianchi's guidance. Catheter Precision received its first commercial purchase order from partner Precise Srl, marking the beginning of broader market access and commercial deployment of LockeT across the region.

Catheter Precision, Inc. (VTAK - NYSE/American), a U.S.-based medical device company focused on cardiac electrophysiology solutions, has announced the introduction of LockeT in Italy following successful procedures and clinical acceptance in France and Germany. The first procedures in Italy were performed at ASST Valle Olona Hospital under the expert guidance of Dr. Manuela Bianchi. This expansion marks a significant milestone for the company and its innovative product line.

LockeT, a suture retention device designed to assist in wound closure after percutaneous venous punctures, has demonstrated versatility and clinical value across diverse healthcare settings. The initial cases in Italy further validate LockeT's potential to streamline procedural efficiency and patient outcomes. Following these successful evaluations, Catheter Precision received its first commercial purchase order from long-time partner and distributor Precise Srl, indicating broader market access and commercial deployment of LockeT across the region.

David Jenkins, CEO of Catheter Precision, expressed optimism about the rapid uptake of LockeT in Europe. He stated, "We are encouraged by the rapid uptake of LockeT acceptance in Europe, the introduction of the product into a third European country so quickly after the CE Mark approval, and the first purchase order. The excitement from physicians for LockeT further demonstrates the need for a product that streamlines closure after catheter ablation procedures while remaining cost-effective."

LockeT is a Class 1 device registered with the FDA and has received CE Mark approval. It is designed to enhance procedural efficiency and patient outcomes after cardiac ablation procedures. The product evaluation in Italy follows similar successful procedures in France and Germany, demonstrating LockeT's potential in the European market.

Catheter Precision continues to advance its product portfolio by collaborating with physicians and continuously improving its technologies. The company's focus on developing innovative solutions for cardiac arrhythmias positions it as a leader in the cardiac electrophysiology market.

References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3142627/0/en/Catheter-Precision-Announces-Introduction-of-the-LockeT-Product-Line-into-Italy.html
[2] https://www.biospace.com/press-releases/catheter-precision-announces-first-procedures-in-france-as-locket-expansion-continues